1. Scrip
  2. >>Therapy Areas

Entresto US Sales Barriers Set To Be Removed By Strong Guidance

 
• By Sten Stovall

Sales prospects for Novartis AG's struggling Entresto have been boosted – especially in the US – by new global cardiology guidelines issued by three organizations containing stronger than expected recommendations for its use in treating heart failure.

Pills and heart

Novartis' novel heart drug, formerly called LCZ696, was given a huge boost when experts from the American College of Cardiology, the American Heart Association and the European Society of Cardiology on May 21 announced that Entresto (valsartan/sacubitril) should replace old ACE inhibitors and ARBs in patients with adequate blood pressure and drug tolerance.

In the US, the twice-a-day medicine is now a standard therapy for heart failure with reduced ejection fraction (HFrEF) as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.